Announcement under Regulation 30 (LODR) for receipt of order

Export Order Hard CurrencyBusiness Updates View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.2%Reaction day

₹98.00

prior close

₹100.69

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.8%+3.3% vs market

Pharmaceuticals peers, median of 149sector+0.0%+4.2% vs sector

On the reaction day the stock moved 3.3 pts more than Nifty Microcap 250 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.1

15m

-0.1

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.2+0.8+3.3+0.0+4.2

Next day

+3.1+1.8+1.2+0.8+2.3

+4.6+1.2+3.4+0.5+4.1

+2.0+1.2+0.9+0.3+1.8

+5.1+1.6+3.5+0.4+4.7

+8.0+1.8+6.2+0.9+7.1

+7.1+2.1+5.0+1.4+5.7

15d

-0.5+3.1-3.6+1.7-2.2

—+0.9—-0.8—

—+3.2—-0.9—

+7.1-1.5+8.7-4.3+11.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Asston Pharmaceuticals has received a purchase order from an international pharma company for supplying various pharmaceutical products. The order value is USD 3,01,090 (approximately ₹2.5 crore) and is to be executed on a delivery-against basis. The order is from a foreign entity and is not a related-party transaction, with no promoter interest in the awarding company. This marks a new international business win for the recently listed Navi Mumbai-based pharma firm.

Likely market impact

This is a modest-sized international order that adds to the company's export order book, though its overall impact on revenue is unclear without further context. For a small-cap company, each new international client win is a positive signal for future business growth and credibility in the global pharma space.